A practical reference on Immune modulation: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-05-01. Anything still debated is marked as such rather than presented as settled.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | About 3.1 kDa | 28 residues, N-terminally acetylated |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Freely soluble in water | Also soluble in aqueous buffers |
| Storage temperature | 2 to 8 °C | Protect from light and moisture |
| Common synonyms | Thymalfasin; Tα1 | Same peptide sequence |
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Terry Peter Gallagher as Axel Zufo, a fossil fuels billionaire Billy Eichner as Waylen Lemming, a crypto billionaire David Pittu as Ronan Wylde, a banking billionaire Julie Halston as Kitty Munson, a multinational retail billionaire Matthew Laureano as Nate, a victim who is tortured and killed by the Assassin and Jeremy Rev Yolanda as Clara Gardner, a transgender scientist and Mike's best friend Lux Pascal as Clara after the transformation Laura Dreyfuss as Jennifer King Robert Harrington as Jefferson, Byron's bodyguard Kelli O'Hara as Juliana Williams, Meyer's wife Hazel Graye as Juliana after the transformation Kaylee Halko as Joey, the teenage daughter of Meyer and Juliana who has progeria Augusta Liv as Joey after the transformation Kevin Cahoon as Tiger "Tig" Forst, one of Byron and Franny's sons Ray Nicholson as Tig after the transformation Eric Petersen as Gunther Forst, one of Byron and Franny's sons Brandon Gillard as Gunther after the transformation Anthony Rapp as a Scientist who worked for the space colonization division of Byron's corporation Emma Halleen as Bella Grant, a school student who becomes fixated on the "Beauty" Annabelle Wachtel as Ruthie, Bella's best friend who is lamenting a failed nose job Paige McGarvin as Ruthie after the transformation Maria Dizzia as Marcy Grant, Bella's mother Daniel Stewart Sherman as Bella's father Carson Rowland as Conor, an employee of Byron's corporation who administers doses of the "Beauty" Ethan Eisenstein as Conor before the transformation Red Concepcion as Sir Ma'am, a social media influencer Sky Kawai as Sir Ma'am after the transformation
=== Biomedical imaging === There are many applications for iron-oxide based nanoparticles in concert with magnetic resonance imaging. Magnetic CoPt nanoparticles are being used as an MRI contrast agent for transplanted neural stem cell detection.
Pharmer.org—A non-profit site providing detailed descriptions of most narcotic analgesics List of controlled substances Archived 2021-04-25 at the Wayback Machine, some of which are classified as "narcotics", in the U.S. Controlled Substances Act (CSA). Not all of the classified ones are chemically narcotic, as described at the top of this page. M. C. Cooke (1860), The Seven Sisters of Sleep, Popular History of the Seven Prevailing Narcotics of the World.
Sources: en.wikipedia.org
== History == Oxandrolone was first made by Raphael Pappo and Christopher J. Jung while at Searle Laboratories, now part of Pfizer and they first described the drug in 1962. They were immediately interested in oxandrolone's very weak androgenic effects relative to its anabolic effects. It was introduced as a pharmaceutical drug in the United States in 1964. Oxandrolone was prescribed to promote muscle regrowth in disorders which cause involuntary weight loss, and is used as part of treatment for HIV/AIDS. It had also been shown to be partially successful in treating cases of osteoporosis. However, in 1989, in part due to bad publicity from its illicit use by bodybuilders, production of Anavar was discontinued by Searle Laboratories. It was picked up by Bio-Technology General Corporation, which changed its name to Savient Pharmaceuticals. In 1995, following successful clinical trials, Savient released it under the brand name Oxandrin. As of 2011 BTG subsequently had won approvals for orphan drug status by the Food and Drug Administration for treating alcoholic hepatitis, Turner syndrome, and HIV-induced weight loss and as an offset to protein catabolism caused by long-term administration of corticosteroids.
Considering all decay modes, various models indicate a shift of the center of the island (i.e., the longest-living nuclide) from 298Fl to a lower atomic number, and competition between alpha decay and spontaneous fission in these nuclides; these include 100-year half-lives for 291Cn and 293Cn, a 1000-year half-life for 296Cn, a 300-year half-life for 294Ds, and a 3500-year half-life for 293Ds, with 294Ds and 296Cn exactly at the N = 184 shell closure. It has also been posited that this region of enhanced stability for elements with 112 ≤ Z ≤ 118 may instead be a consequence of nuclear deformation, and that the true center of the island of stability for spherical superheavy nuclei lies around 306Ubb (Z = 122, N = 184). This model defines the island of stability as the region with the greatest resistance to fission rather than the longest total half-lives; the nuclide 306Ubb is still predicted to have a short half-life with respect to alpha decay. The island of stability for spherical nuclei may also be a "coral reef" (i.e., a broad region of increased stability without a clear "peak") around N = 184 and 114 ≤ Z ≤ 120, with half-lives rapidly decreasing at higher atomic number, due to combined effects from proton and neutron shell closures. Another potentially significant decay mode for the heaviest superheavy elements was proposed to be cluster decay by Romanian physicists Dorin N. Poenaru and Radu A. Gherghescu and German physicist Walter Greiner.
=== Baháʼí Faith === While there are no dietary restrictions in the Baháʼí Faith, `Abdu'l-Bahá, the son of the religion's founder, noted that a vegetarian diet consisting of fruits and grains was desirable, except for people with a weak constitution or those that are sick. He stated that there are no requirements that Baháʼís become vegetarian, but that a future society should gradually become vegetarian. `Abdu'l-Bahá also stated that killing animals was contrary to compassion. While Shoghi Effendi, the head of the Bahá'í Faith in the first half of the 20th century, stated that a purely vegetarian diet would be preferable since it avoided killing animals, both he and the Universal House of Justice, the governing body of the Baháʼís have stated that these teachings do not constitute a Baháʼí practice and that Baháʼís can choose to eat whatever they wish but should be respectful of others' beliefs.
Sources: en.wikipedia.org
It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.
The name traces back to thymosin fraction 5, a crude thymus extract examined in the 1970s. Individual peptides in that mixture were labeled with Greek letters, and alpha-1 was one of them. The international nonproprietary name thymalfasin was assigned later.
No. Thymosin beta-4 contains 43 residues and binds actin, while thymosin alpha-1 contains 28 residues and acts on immune cells. The two sit in a historical naming group but share no sequence similarity, and they are not substitutes for one another.
Its sequence corresponds to the amino-terminal portion of prothymosin alpha, a larger protein present in many cell types. The isolated 28-residue peptide is a fragment of that protein rather than a separately encoded molecule, and laboratory material is produced by synthesis.